Loading
ALG.APV-527 is an antibody-like protein from Aptevo Therapeutics that switches on immune cells only where it finds a marker on tumour cells. It is being tested in several kinds of solid tumour.
ALG.APV-527 is a 4-1BB x 5T4 bispecific candidate built on Aptevo Therapeutics' ADAPTIR platform. Aptevo's August 2026 filing states that it is designed to reactivate antigen-primed T cells to kill tumour cells and is being evaluated clinically in multiple solid tumour types; the filing does not state the phase.
Binds the co-stimulatory receptor 4-1BB on T cells and the tumour antigen 5T4, designed to reactivate antigen-primed T cells at the tumour, as described by Aptevo Therapeutics. Connects to CD137 (4-1BB, TNFRSF9).
1.One arm of ALG.APV-527 binds CD137 (4-1BB, TNFRSF9) on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ALG.APV-527" OR ABSTRACT:"ALG.APV-527") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ALG.APV-527, not a curated reading list.
Shares Aptevo Therapeutics and the tag pipeline.
Shares CD137 (4-1BB, TNFRSF9) and the tag pipeline.
Shares CD137 (4-1BB, TNFRSF9) and the tag pipeline.
Shares Bispecific antibodies and the tag pipeline.
Shares Bispecific antibodies and the tag pipeline.
Shares Bispecific antibodies and the tag pipeline.
Shares Bispecific antibodies and the tag pipeline.
Shares Bispecific antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/